MX2019006943A - Polipéptidos para manejo de infecciones virales. - Google Patents

Polipéptidos para manejo de infecciones virales.

Info

Publication number
MX2019006943A
MX2019006943A MX2019006943A MX2019006943A MX2019006943A MX 2019006943 A MX2019006943 A MX 2019006943A MX 2019006943 A MX2019006943 A MX 2019006943A MX 2019006943 A MX2019006943 A MX 2019006943A MX 2019006943 A MX2019006943 A MX 2019006943A
Authority
MX
Mexico
Prior art keywords
polypeptides
viral infections
managing viral
managing
yodha
Prior art date
Application number
MX2019006943A
Other languages
English (en)
Spanish (es)
Inventor
JACOB Joshy
Holthausen David
Hee Lee Song
SHARTOUNY Jessica
GEORGE Sanil
Original Assignee
Univ Emory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Emory filed Critical Univ Emory
Publication of MX2019006943A publication Critical patent/MX2019006943A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/463—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from amphibians
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
MX2019006943A 2016-12-13 2017-12-01 Polipéptidos para manejo de infecciones virales. MX2019006943A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662433490P 2016-12-13 2016-12-13
US201762466066P 2017-03-02 2017-03-02
PCT/US2017/064330 WO2018111580A1 (en) 2016-12-13 2017-12-01 Polypeptides for managing viral infections

Publications (1)

Publication Number Publication Date
MX2019006943A true MX2019006943A (es) 2019-10-21

Family

ID=62559193

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019006943A MX2019006943A (es) 2016-12-13 2017-12-01 Polipéptidos para manejo de infecciones virales.

Country Status (8)

Country Link
US (2) US10898544B2 (https=)
EP (2) EP3909598A1 (https=)
JP (1) JP2020513418A (https=)
CN (1) CN110325206A (https=)
AU (1) AU2017377993A1 (https=)
CA (1) CA3046927A1 (https=)
MX (1) MX2019006943A (https=)
WO (1) WO2018111580A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6148233B2 (ja) 2011-07-11 2017-06-21 インディ モレキュラー，インコーポレイテッド Ａｋｔ特異的捕捉剤、組成物ならびにその使用および製造方法
CN107624115B (zh) 2015-03-16 2021-10-26 加州理工学院 肉毒神经毒素特异性捕获剂、组合物、使用方法和制造方法
EP3322716B1 (en) 2015-07-15 2025-02-12 California Institute of Technology Il-17f-specific capture agents and methods of using
EP3440101B1 (en) 2016-04-04 2021-10-06 Indi Molecular, Inc. Cd8-specific capture agents, compositions, and methods of using and making
US11884707B2 (en) 2016-09-29 2024-01-30 Regeneron Pharmaceuticals, Inc. Compositions for detection, inhibition and imaging of indoleamine 2, 3-dioxygenase 1 (IDO1) and methods of making and using same
CA3046927A1 (en) 2016-12-13 2018-06-21 Emory University Polypeptides for managing viral infections
WO2018232345A1 (en) 2017-06-15 2018-12-20 Indi Molecular, Inc. Il-17f and il-17a-specific capture agents, compositions, and methods of using and making
US12201679B2 (en) * 2019-04-05 2025-01-21 Institute For Systems Biology Epitope-targeted peptide immunostimulants
US12216122B2 (en) 2019-05-20 2025-02-04 Regeneron Pharmaceuticals, Inc. Compositions and methods relating to detection, inhibition, and imaging of indoleamine 2,3-dioxygenase 1 (IDO1)
US12209142B2 (en) 2020-05-29 2025-01-28 Institute For Systems Biology SARS-CoV-2 epitope-targeted peptide immunostimulants
WO2022098743A1 (en) 2020-11-03 2022-05-12 Indi Molecular, Inc. Compositions, imaging, and therapeutic methods targeting folate receptor 1 (folr1)

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US598520A (en) 1898-02-08 Marker s record for laundrymen
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
US4966848A (en) * 1988-02-08 1990-10-30 The General Hospital Corporation Isolation, purification, characterization, cloning and sequencing of N α-acetyltransferase
US5223421A (en) * 1989-10-25 1993-06-29 The General Hospital Corporation Identification of methionine Nα-acetyltransferase
CA2109528A1 (en) 1991-05-01 1992-11-02 Gregory A. Prince A method for treating infectious respiratory diseases
IS2334B (is) 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US5688489A (en) * 1995-09-15 1997-11-18 Resolution Pharmaceuticals, Inc. Non-receptor mediated imaging agents
US6043358A (en) 1995-11-01 2000-03-28 Merck & Co., Inc. Hexahydro-5-imino-1,4-heteroazepine derivatives as inhibitors of nitric oxide synthases
ATE508733T1 (de) 1996-03-04 2011-05-15 Penn State Res Found Materialien und verfahren zur steigerung der zellulären internalisierung
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
SE9604593D0 (sv) * 1996-12-13 1996-12-13 Sbl Vaccin Ab Antimicrobially active polypeptides
CA2277801C (en) 1997-01-16 2002-10-15 Massachusetts Institute Of Technology Preparation of particles for inhalation
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
WO1999066903A2 (en) 1998-06-24 1999-12-29 Advanced Inhalation Research, Inc. Large porous particles emitted from an inhaler
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US20070207209A1 (en) * 2004-08-27 2007-09-06 Murphy Christopher J Trophic factor combinations for nervous system treatment
CN102448438A (zh) * 2009-03-26 2012-05-09 普马特里克斯公司 抗流行性感冒调配物及方法
US9464124B2 (en) * 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2755986A4 (en) * 2011-09-12 2015-05-20 Moderna Therapeutics Inc MANIPULATED NUCLEIC ACIDS AND METHOD OF APPLICATION THEREFOR
US20140296137A1 (en) * 2013-04-01 2014-10-02 Los Alamos National Security, Llc Methods and compositions for controlling rotifers
CA3046927A1 (en) 2016-12-13 2018-06-21 Emory University Polypeptides for managing viral infections

Also Published As

Publication number Publication date
EP3909598A1 (en) 2021-11-17
JP2020513418A (ja) 2020-05-14
EP3554533A1 (en) 2019-10-23
US11666630B2 (en) 2023-06-06
EP3554533A4 (en) 2020-07-15
US20190307840A1 (en) 2019-10-10
CA3046927A1 (en) 2018-06-21
US20210138029A1 (en) 2021-05-13
AU2017377993A1 (en) 2019-07-04
CN110325206A (zh) 2019-10-11
WO2018111580A1 (en) 2018-06-21
US10898544B2 (en) 2021-01-26
EP3554533B1 (en) 2021-06-09

Similar Documents

Publication Publication Date Title
MX2019006943A (es) Polipéptidos para manejo de infecciones virales.
PH12020500396A1 (en) Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1) inhibitors and uses thereof
PH12017500949A1 (en) Human antibodies to influenza hemagglutinin
EA201890731A1 (ru) Модуляторы корового белка гепатита b
EP3936141A3 (en) Anti-senescence compounds and uses thereof
PH12018501962A1 (en) Stablizied soluble pre-fusion rsv f proteins
EA201990071A1 (ru) Композиция пептидной вакцины
PH12020500569A1 (en) Influenza virus vaccines and uses thereof
PH12017500450A1 (en) Flavivirus virus like particle
AR120721A2 (es) Péptidos y composiciones para el tratamiento de daño articular
MX2016007626A (es) Peptido antimicrobiano y usos del mismo.
BR112014028130A2 (pt) Sal de cloridrato de um peptídeo, composição farmacêutica, uso de um sal de cloridrato, uso de uma composição farmacêutica, e, método para evitar ou tratar alergia a gatos
MX2017003928A (es) Composiciones farmaceuticas de accion prolongada.
PH12017502386B1 (en) Methods of purification and/or viral inactivation
MX2019006768A (es) Peptidos antimicrobianos.
GB2544439A (en) Antiviral composition
MX362058B (es) Péptido pntx(19) sintético, composición farmacéutica y uso.
MX2018002616A (es) Proteina de fusion.
WO2015041924A3 (en) Recombinant respiratory syncytial virus (rsv) and caccines
PH12017500816A1 (en) Long acting pharmaceutical compositions for hepatitis c
PH12017500820A1 (en) Combination long acting compositions and methods for hepatitis c
EA201791456A1 (ru) Пептиды-антагонисты cgrp
MX360137B (es) Proteínas h5 del virus de la influenza h5n1 para usarse como un medicamento.
MX2018000384A (es) Composiciones para el tratamiento contra infecciones.
TR201910305T4 (tr) Viral enfeksiyonları tedavi etmek için bileşikler.